Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 5/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17097419 | 1.00 | NR3C1 (0.33) | NR3C1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17098772 | 0.95 | RORC (0.34) | NR3C1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17098774 | 0.95 | RORC (0.34) | NR3C1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17098493 | 0.92 | RORC (0.39) | RORC | |
| SCHEMBL17098673 | 0.92 | RORC (0.33) | NR3C1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17098670 | 0.92 | RORC (0.33) | NR3C1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17098496 | 0.92 | RORC (0.39) | RORC | |
| SCHEMBL17099181 | 0.90 | HSD11B1 (0.35) | NR3C1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17099183 | 0.90 | HSD11B1 (0.35) | NR3C1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17097667 | 0.90 | HSD11B1 (0.31) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | claimed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | claimed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | NR3C1 66/4885CYP1A2 388/4885CYP3A4 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.